The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety results of FGFR1-3 inhibitor, tinengotinib, as monotherapy in patients with advanced, metastatic cholangiocarcinoma: Results from phase II clinical trial.
 
Milind M. Javle
Honoraria - AstraZeneca/MedImmune; EMD Serono/Merck; Incyte; Merck; QED Therapeutics; TransThera Biosciences
Consulting or Advisory Role - AstraZeneca; Basilea Pharmaceutical; EMD Serono; incyte; Merck; Mundipharma; oncosil; QED Therapeutics
Other Relationship - Bayer; BeiGene; Incyte; Merck; Merck Serono; Novartis; Pieris Pharmaceuticals; QED Therapeutics; Rafael Pharmaceuticals; Seagen
 
Amit Mahipal
Consulting or Advisory Role - AstraZeneca/MedImmune; QED Therapeutics; Taiho Oncology
Speakers' Bureau - AstraZeneca
Research Funding - Taiho Pharmaceutical
 
Lionel Aurelien Kankeu Fonkoua
Honoraria - Exelixis (Inst); Incyte (Inst)
Consulting or Advisory Role - Exelixis (Inst); Incyte (Inst)
 
Christos Fountzilas
Research Funding - Amgen (Inst); Aravive (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bellicum Pharmaceuticals (Inst); Biomea Fusion (Inst); Bristol-Myers Squibb/Ono Pharmaceutical (Inst); Corcept Therapeutics (Inst); CrystalGenomics (Inst); Dragonfly Therapeutics (Inst); ERYTECH Pharma (Inst); Incyte (Inst); Ipsen (Inst); Kadmon (Inst); Kinex (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Rafael Pharmaceuticals (Inst); Seagen (Inst); Syndax (Inst); Taiho Oncology (Inst); TransThera Biosciences (Inst)
Travel, Accommodations, Expenses - CG Pharmaceuticals
 
Daneng Li
Consulting or Advisory Role - AstraZeneca; Delcath Systems; Eisai; Exelixis; Genentech; Merck; Sumitomo Pharma Oncology; Tersera; TransThera Biosciences
Speakers' Bureau - Eisai; Exelixis; Ipsen; SERVIER; Tersera
Research Funding - AstraZeneca (Inst); Brooklyn ImmunoTherapeutics (Inst)
 
Meredith Pelster
Honoraria - Castle Biosciences (I)
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst)
Research Funding - 1200 Pharma (Inst); Actuate Therapeutics (Inst); Agenus (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); BeiGene (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Codiak Biosciences (Inst); Compass Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); Elevation Oncology (Inst); Exelixis (Inst); Gilead Sciences (Inst); HiberCell (Inst); Immune-Onc Therapeutics (Inst); Leap Therapeutics (Inst); Novartis (Inst); OncXerna Therapeutics (Inst); Panbela Therapeutics (Inst); Revolution Medicines (Inst); SQZ Biotechnology (Inst); Surface Oncology (Inst); Tachyon Therapeutics (Inst); Translational Genomics Research Institute (Inst); TransThera Sciences (Nanjing), Inc. (Inst); ZielBio (Inst)
 
Chih-Yi Liao
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Exelixis; Genentech; Histosonics; Incyte; Ipsen; Lexicon; Lilly; QED Therapeutics; TransThera Biosciences
Speakers' Bureau - AstraZeneca; Eisai; Exelixis; Incyte
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - AstraZeneca; Eisai; Exelixis; Incyte; Ipsen
 
Donald A. Richards
Consulting or Advisory Role - Grail; Ipsen; Mirati Therapeutics; Seattle Genetics/Astellas; Taiho Pharmaceutical
 
Dustin A. Deming
Consulting or Advisory Role - Bayer; Lilly; Pfizer; Seagen
Research Funding - AADi (Inst); Arcus Ventures (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Curegenix (Inst); Genentech (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst); Natera (Inst); Promega (Inst); Revolution Medicines (Inst); Strata Oncology (Inst)
 
Mohamad Ahmad Younes
Employment - New York Oncology Hemotology
 
Parvez Mantry
No Relationships to Disclose
 
Allen Lee Cohn
Honoraria - Amgen
Expert Testimony - Department of Justice
 
Ed Kingsley
No Relationships to Disclose
 
Jean Fan
Employment - TransThera Biosciences
Leadership - TransThera Biosciences
Stock and Other Ownership Interests - AstraZeneca
 
Peng Peng
Employment - TransThera Sciences (Nanjing), Inc.
Stock and Other Ownership Interests - TransThera Sciences (Nanjing), Inc.
Patents, Royalties, Other Intellectual Property - PCT/CN2022/091924 (Inst)
 
Caixia Sun
Employment - TransThera Sciences (Nanjing), Inc.
 
Hui Wang
No Relationships to Disclose
 
Katie Hennessy
Employment - TransThera Biosciences
Travel, Accommodations, Expenses - TransThera Biosciences
 
Yujun Shan
No Relationships to Disclose
 
Frank Wu
Leadership - TransThera Sciences (Nanjing), Inc.